PARMAR KUSH (CIK 1664281) reported 30 SEC Form 4 insider transactions across 4 companies over the past 18 months (most recent 2026-08-20). Recent activity: Sell SKYE (45,090 shares), Sell SKYE (1,830 shares), Sell SKYE (253,080 shares), Sell SKYE (10,255 shares), Sell SKYE (409 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-20 | Skye Bioscience, Inc. (SKYE) | 10% Owner | Sell | 45,090 | $17,134 |
| 2026-08-20 | Skye Bioscience, Inc. (SKYE) | 10% Owner | Sell | 1,830 | $695 |
| 2026-08-20 | Skye Bioscience, Inc. (SKYE) | 10% Owner | Sell | 253,080 | $96,170 |
| 2026-08-20 | Skye Bioscience, Inc. (SKYE) | 10% Owner | Sell | 10,255 | $3,589 |
| 2026-08-20 | Skye Bioscience, Inc. (SKYE) | 10% Owner | Sell | 409 | $143 |
| 2026-08-20 | Skye Bioscience, Inc. (SKYE) | 10% Owner | Sell | 57,476 | $20,117 |
| 2026-08-20 | Skye Bioscience, Inc. (SKYE) | 10% Owner | Sell | 1,159 | $371 |
| 2026-08-20 | Skye Bioscience, Inc. (SKYE) | 10% Owner | Sell | 46 | $15 |
| 2026-08-20 | Skye Bioscience, Inc. (SKYE) | 10% Owner | Sell | 6,495 | $2,078 |
| 2026-08-12 | Latigo Biotherapeutics, Inc. (LTGO) | 10% Owner | Buy | 5.0M | $0 |
| 2026-08-12 | Latigo Biotherapeutics, Inc. (LTGO) | 10% Owner | Buy | 2.4M | $0 |
| 2026-08-10 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 52,317 | $358,371 |
| 2026-08-10 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 10,494 | $73,458 |
| 2026-08-10 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 92,444 | $647,108 |
| 2026-08-03 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 114,756 | $795,259 |
| 2026-08-03 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 1,718 | $11,768 |
| 2025-11-18 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 200,000 | $1.8M |
| 2025-09-15 | Camp4 Therapeutics Corp (CAMP) | Insider | Buy | 2.9M | $4.5M |
| 2025-08-22 | Skye Bioscience, Inc. (SKYE) | Insider | Sell | 58,642 | $209,352 |
| 2025-08-22 | Skye Bioscience, Inc. (SKYE) | Insider | Sell | 2,314 | $8,261 |
| 2025-08-22 | Skye Bioscience, Inc. (SKYE) | Insider | Sell | 163,979 | $560,808 |
| 2025-08-22 | Skye Bioscience, Inc. (SKYE) | Insider | Sell | 6,470 | $22,127 |
| 2025-07-11 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 20,065 | $150,488 |
| 2025-07-11 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 6,935 | $52,012 |
| 2025-07-01 | Entrada Therapeutics, Inc. (TRDA) | Director | Sell | 55,735 | $385,129 |
Source: SEC Form 4 filings · as of 2026-08-20